This phase II trials studies the effects of yttrium-90 labeled anti-CD25 monoclonal antibody combined with BEAM chemotherapy conditioning in treating patients with Hodgkin lymphoma that does not response to treatment (refractory) or has come back (relapsed). Yttrium-90-labeled anti-CD25 is an antibody (proteins made by the immune system to fight infections) that is attached to a radioactive substance and may kill cancer cells and shrink tumors. Chemotherapy drugs, such as carmustine, etoposide, cytarabine, and melphalan, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before a peripheral blood stem cell transplant helps kill cancer cells in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow.
Age: ≥18 years
Karnofsky performance status ≥ 70%
Life expectancy ≥ 6 months Nature of Illness and Illness Related Criteria
Histologically confirmed HL
Planned BV consolidation after AHCT
Prior high dose chemotherapy with autologous stem cell transplant, or prior allogeneic transplantation.
Significant prior external beam dose-limiting radiation to a critical organ based on review of the prior radiation treatment records by the Radiation Oncology PI.
Patients may not be receiving any other investigational agents, or concurrent biological, chemotherapy, or radiation therapy.
City of Hope Medical Center
Lead sponsor
National Cancer Institute (NCI)
Collaborator